️<unk>️<unk>️<unk>️  ️<unk>️<unk>️<unk>️<unk>️<unk>️<unk>️<unk>️<unk>️<unk>️<unk>️<unk>️<unk>️<unk>️<unk>️<unk>️<unk>️<unk>️<unk>️<unk>️<unk>️ ️<unk>️<unk>️<unk>️<unk>️<unk>️<unk>️<unk>️<unk>️<unk>️<unk>️<unk>️<unk>️<unk>️<unk>️<unk>️ ️<unk>️<unk>️<unk>️<unk>️<unk>️<unk>️<unk>️<unk>️<unk>️<unk>️<unk>️<unk>️<unk>️<unk>️<unk>️<unk>️<unk>️<unk>️<unk>️ ️<unk>️<unk>️<unk>️<unk>️<unk>️<unk>️<unk>️<unk>️<unk>️<unk>️<unk>️<unk>️<unk>️<unk>️ ️<unk>️<unk>️<unk>️<unk>️<unk>️<unk>️<unk>️<unk>️<unk>️<unk>️<unk>️<unk>️<unk>️<unk>️<unk>️<unk>️<unk>️<unk>️<unk>️<unk>️<unk>️<unk>️<unk>️<unk>️<unk>️<unk>️<unk>️<unk>️<unk>️<unk>️<unk>️<unk>️<unk>️<unk>️<unk>️<unk>️<unk>️<unk>️<unk>️<unk>️<unk>️<unk>️<unk>️<unk>️<unk>️<unk>️<unk>️<unk>️<unk>️<unk>️<unk>️<unk>️<unk>️<unk>️<unk>️<unk>️<unk>️<unk>️<unk>️<unk>️<unk>️<unk>️<unk>️<unk>️<unk>️<unk>️<unk>️<unk>️<unk>️<unk>️<unk>️<unk>️<unk>️<unk>️<unk>️<unk>️<unk>️<unk>️<unk>️<unk>️<unk> Many potential Alzheimer's drugs never quite make it,<unk> says Biogen spokesperson Kate Niazo-Sai. Mais les résultats que nous avons observés sur un échantillon de patients relativement petit sont très prometteurs. <unk><unk><unk><unk><unk><unk><unk><unk><unk><unk><unk><unk><unk><unk><unk><unk><unk><unk><unk><unk><unk><unk><unk><unk><unk><unk><unk><unk><unk><unk><unk><unk><unk><unk><unk><unk><unk><unk><unk><unk><unk><unk><unk><unk><unk><unk><unk><unk><unk><unk><unk><unk><unk><unk><unk><unk><unk><unk><unk><unk><unk><unk><unk><unk><unk><unk><unk><unk><unk><unk><unk><unk><unk><unk><unk><unk> Biogen, the pharmaceutical firm that developed the drug, called aduncanumab, wants to recruit at least 1,000 patients for tests (picture posed by model) The trial shows that aduncanumab significantly reduces amyloid plaque <unk> clumps of protein typically found in the brains of Alzheimer<unk>s patients. ️<unk>️<unk>️<unk>️<unk>️<unk>️<unk>️<unk> Dr Eric Karran, director of research at Alzheimer's Research UK, says the drug could prove an effective<unk> and safe<unk> treatment. Dr Eric Karran, director of research at Alzheimer's Research UK, says the drug could prove an effective<unk> and safe<unk> treatment. These are very promising early results. <unk>These are very promising early results. <unk>These are very promising early results. It will be important to see results from much larger trials before we can understand how effective this treatment may be.<unk> It will be important to see results from much larger trials before we can understand how effective this treatment may be.<unk> The year-long early-stage trial saw 166 patients with mild or early symptoms of Alzheimer' s given either aduncanumab in varying doses, or a...
<unk> <unk> <unk> <unk> <unk> <unk> <unk> <unk> <unk> <unk> <unk> <unk> <unk> <unk> <unk> <unk> <unk> <unk> <unk> <unk> <unk> <unk> <unk> <unk> <unk> <unk> <unk> <unk> <unk> <unk> <unk> <unk> <unk> <unk> <unk> <unk> <unk> <unk> <unk> <unk> <unk>